Search

everythinglearnresearchcommunity

for

Search:↓

Leptin-deficient mice, used as a model for Type 2 Diabetes, have delayed wound healing due to impaired contraction and other dysfunctional cellular responses.

Anti-IL-12/IL-23 antibody therapy effectively treats psoriasiform skin lesions in IBD patients.

Higher IL-17A and IL-23 levels are linked to alopecia areata severity and could help in tracking and treating the disease.

IL-17 inhibitors for psoriasis may cause unexpected hair loss.

Higher IL-17A levels indicate more severe alopecia areata.

Targeting IL-17 could help treat pattern hair loss.

Blocking IL-17 can reduce skin inflammation in a mouse model of pityriasis rubra pilaris.

Alopecia areata involves immune system imbalances that may lead to depression and anxiety.

Mesenchymal stem cells in people with Hidradenitis Suppurativa are more inflammatory, possibly contributing to the disease.

Increased Toll-like receptors in blood cells may contribute to alopecia areata and could be a target for new treatments.

Secukinumab effectively treated a difficult case of folliculitis decalvans.

A medication may help with hair growth in psoriasis, and a skin condition might be linked to a specific bacteria.

Secukinumab for psoriasis may cause hair loss.

Finasteride may help treat autism by reducing inflammation and oxidative stress.

Alopecia areata is a hair loss disease caused by complex immune reactions, and new targeted treatments show promise.

An elderly man's hair grew back after treatment with secukinumab, possibly due to reduced scalp inflammation or the medication's direct effects.

Switching from adalimumab to ixekizumab improved a patient's psoriasis and reversed hair whitening.

Two patients with psoriasis grew extra hair after using certain psoriasis medications.

Certain gene variations are linked to alopecia areata.

Certain immune-related proteins are higher in people with alopecia and their healthy relatives, hinting at a genetic link.

TAK-279 effectively reduces psoriasis symptoms and is safe.

Bimekizumab effectively treated a man's chronic beard hair loss.

Higher levels of certain proteins in the blood are linked to more severe patchy alopecia areata.

Secukinumab can cause hair loss, which may improve after stopping the medication.

Type 1/17 inflammation in psoriasis increases skin cell growth due to a molecule that could be a new treatment target.

Higher Interleukin 17A levels may indicate more severe alopecia areata.

Cholecystokinin may help reduce skin inflammation in psoriasis.

Secukinumab reduces immune activity in hidradenitis suppurativa skin.

PCOS causes inflammation regardless of body weight.

Biologics and JAK inhibitors may improve treatment for scarring alopecias.